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Cryptococcemia is a bloodstream fungal infection caused by encapsulated yeasts of Cryptococcus neo-
formans. We reported an 88-year-old woman in whom C. neoformans colonies of smooth and mucoid
phenotypes were sequentially cultured from the blood during treatment of retroperitoneal diffuse large
B-cell lymphoma using rituximab-containing chemotherapy. The most likely cause was disease pro-
gression of pulmonary cryptococcoma. She was successfully treated with optimal antifungal therapy.
Copyright © 2016, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Cryptococcus neoformans is the most common encapsulated
yeast that causes opportunistic cryptococcosis in immunocom-
promised patients. The molecular type of C. neoformans can be
subdivided into VNI, VNII, VNB (C. neoformans var. grubii), VNIV
(C. neoformans var. neoformans), and VNIII (a hybrid form of 2 va-
rieties). The subtype VNI is the leading cause of cryptococcosis
worldwide, including Taiwan1. The morphology of Cryptococcus
colonies can be depicted as smooth (SM) or mucoid (MC)2. Fries
et al2 described the morphology change between SM and MC as
phenotypic switching. It is a reversible process, in which colony
morphology changes to another variant at a higher frequency than
would be expected from random somatic mutation.
Rituximab-containing cyclophosphamide, hydroxydaunor-
ubicin, oncovin, and prednisolone (CHOP) chemotherapy is one of
the regimens indicated for diffuse large B-cell lymphoma.re that they have no conﬂicts
chool of Medicine, MacKay
Road, Sanzhi District, New
ng).
atric Emergency & Critical Care M
censes/by-nc-nd/4.0/).Rituximab is a monoclonal antibody for CD20-positive B lympho-
cyte. However, opportunistic infections have been reported due to
the immunosuppressive effect of rituximab3,4.
2. Case Report
An 88-year-old woman had a history of right breast cancer,
Stage IIA postmastectomy, and lymph node dissection in April
2010. Since then she has received oral tamoxifen adjuvant ther-
apy until December 2012. In December 2012, she presented with
right ﬂank and abdominal pain with weight loss of <10% of body
weight (5 kg) within 3 months. A large soft tissue lesion
(9.3 cm 5.4 cm 9.3 cm) in the retroperitoneal aortocaval and
para-aortic region was found by abdominal computed tomogra-
phy scan. Biopsy of the retroperitoneal mass revealed CD20-
positive diffuse large B-cell lymphoma. In addition, one 2-mm
peripheral nodule at the right upper lung and another 3-mm
nodule at the left upper lung without deﬁnite characteristics
on chest computed tomography scan (Figure 1A) were found
during staging workup. Bone marrow needle biopsy showed no
bone marrow involvement. Thus, her diffuse large B-cell lym-
phoma was classiﬁed as Stage IIA disease. Her Eastern Coopera-
tive Oncology Group performance score was 2. The level of
lactate dehydrogenase was 261 IU/L. The International Prognosticedicine. Published by Elsevier Taiwan LLC. This is an open access article under the
Figure 1. (A) Chest computer tomography revealed two peripheral nodules (black arrows). (B) Summary of morphology change and antifungal treatment. AMB þ 5FC ¼
amphotericin B plus ﬂucytosine; MC¼mucoid; MS-CNS¼methicillin-susceptible coagulase-negative Staphylococcus; SM¼ smooth.
Cryptococcemia in an Elderly Woman 113Index score was 3, which placed her in the higheintermediate
risk group. She was ﬁrst treated with a prephase therapy con-
taining dexamethasone plus vincristine in January 2013. One
week later, she was treated with rituximab, cyclophosphamide,
vincristine, and prednisolone combination chemotherapy. The
dose of rituximab was 375 mg/m2 during treatment. Three weeks
later, she received a second course of treatment with rituximab
and prednisolone to minimize side effects.
On the third admission for chemotherapy, rituximab, vincris-
tine, and prednisolone combination therapy was given on February
19, 2013 (Day 0). Fever developed 8 days later, and she received
empirical antibiotics after obtaining urinalysis and blood culture
(BACTEC FX culture system; Becton Dickinson, Inc., Sparks, MD,
USA). Laboratory data (Day 8) showed that white blood cells countwas 1600/mL with 4% band, 64% neutrophil, and 26% lymphocyte.
She had a C-reactive protein level of 5.18 mg/dL, procalcitonin level
of 0.063 ng/mL, and creatinine level of 0.8 mg/dL. Granulocyte
colony-stimulating factor was administered due to neutropenia.
Blood culture yielded methicillin-susceptible coagulase-negative
Staphylococcus; fever subsided gradually after adequate antibiotic
use. However, her urine culture yielded yeast (Figure 1B). OnMarch
4, 2013 (Day 13), we repeated blood cultures due to neutropenic
fever. Three days later (Day 16), the preliminary report from blood
culture revealed yeast. Initially, a 400-mg dose of intravenous ﬂu-
conazolewas administered empirically; the antifungal regimenwas
then pre-emptively switched to micafungin 100 mg once daily on
the next day (Day 17) to cover clinically suspected azole-resistant
Candida.
M.-W. Cheng et al.114The yeasts from urine and blood cultures were subsequently
identiﬁed to be Cryptococcus species through positive India ink and
urease test. The morphology of Cryptococcus species was round
with smooth (SM) dome colony surface and thin capsule (Figure 2).
The antifungal regimen was thus switched to an induction therapy
for cryptococcemia5, consisting of intravenous amphotericin B
(0.7 mg/kg/d) plus oral ﬂucytosine 1000mg/6 h for a 14-day course.
The serum cryptococcal antigen titer was 1024-fold. Although there
was a high concern for central nervous system invasion by Cryp-
tococcus species (SM), she declined lumbar puncture due to per-
sonal reasons. In the beginning, Cryptococcus species (SM) in urine
and blood culture was identiﬁed as Cryptococcus laurentii through
VITEK 2 system (bioMerieux, Marcy l'Etoile, France). C. laurentii, a
possible saprophyte from skin, has rarely been reported as a human
pathogen.
On March 7, 2013 (Day 16), we performed follow-up blood
culture and Cryptococcus species (SM) was reported again. Inter-
estingly, a few shiny and mucoid-appearing colonies (MC; Figure 3)
were found and identiﬁed as C. neoformans by VITEK 2 system. On
March 11, 2013 (Day 20), we carried out another blood culture; both
SM and MC colonies were found. The antifungal susceptibility test
of SM and MC revealed no signiﬁcant difference in amphotericin B,
ﬂuconazole, itraconazole, voriconazole, posaconazole, and ﬂucy-
tosine by a commercially prepared, dried colorimetric micro-
dilution panel of Sensitire YeastOne (TREK Diagnostic Systems,
Units 17-19 Birches Industrial Estate, East Grinstead, West Sussex.
RH19 1XZ, UK) (Table 1). High-molecular-weight DNA of both SM
and MC yeasts were extracted; genotypes were determined by
URA5 gene restriction fragment length polymorphism (RFLP)
analysis6. The results of molecular typing of both SM andMC yeasts
revealed VNI, a major subtype in Taiwan1, excluding the infection
cause by C. laurentii.
On March 18, 2013 (Day 27), the third set of followed-up blood
culture turned out to be sterile. Antifungal consolidation therapyFigure 2. Colonies of Cryptococcus neoformans had smooth border on (A) sheep blood agar
enlarged photo of one cryptococcal cell from square frame in Figure 2C. SM¼ smooth.with ﬂuconazole 400 mg orally started after 2-week induction
therapy5. She recovered slowly without any neurological sequelae
and was discharged on Day 139 with a maintenance dose of ﬂu-
conazole 200 mg/d orally. Due to old age and the deteriorated
performance status of the patient, the family decided not to receive
further chemotherapy, and the clinical course of the patient was
uneventful after that. Eventually, she passed away 1 year later due
to an episode of respiratory infection at the age of 90 years.
3. Discussion
In most developed countries including Taiwan, the aging pop-
ulation continues to grow to a larger percentage of the overall
population. It was generally agreed that older persons are prone to
infections. However, with adequate therapy, age may not be a sig-
niﬁcant predictor of mortality for sepsis, even in critically ill pa-
tients7. The application of sepsis bundles including obtaining
routine culture before the administration of broad-spectrum anti-
biotics has been effective and has led to a substantial reduction in
hospital mortality8. In a cohort comparing clinical characteristics of
cryptococcal meningitis in elderly patients (aged 65 years) with
those in younger patients, there was no difference in mortality
rate9. We had successfully treated this 88-year-old woman for her
cryptococcemia through proper blood culture identiﬁcation and
feasible antifungal therapy implementation according to treatment
guidelines5.
We hypothesized that cryptococcemia in this elderly woman
was a disease progression of pulmonary cryptococcoma during
immunosuppression rather than a recent infection from bird
droppings or other environmental source because she reported no
such exposure history. In the absence of immune clearance, the
fungus proliferates in the phagosomes of alveolar macrophages.
Free yeast cells or those present in phagocytic cells entered the
bloodstream and reached the urinary tract to cause cryptococcemiaand (B) potato dextrose agar; (C) SM colony cells in India ink (1000 with oil) and (D)
Figure 3. Colonies of Cryptococcus neoformans had mucoid phenotype on (A) SBA and (B) PDA; (C) MC colony cells and (D) enlarged photo of one cryptococcal cell from the square
frame in Figure 3C. MC¼mucoid; PDA¼ potato dextrose agar; SBA¼ sheep blood agar.
Table 1
Minimum inhibitory concentration of antifungal susceptibility of Cryptococcus
neoformans by the commercial microdilution panel Sensititre YeastOne.
Antifungal Smooth Mucoid
MIC (mg/mL) MIC (mg/mL)
Amphotericin B 0.25 0.25
Fluconazole 8 8
Itraconazole 0.12 0.12
Voriconazole 0.06 0.03
Posaconazole 0.25 0.12
5-Flucytosine 4 4
Caspofungin 8 8
Micafungin 8 8
Anidulafungin 8 8
MIC¼minimum inhibitory concentration.
Cryptococcemia in an Elderly Woman 115and cryptococcuria in this case. We raised two clinical observations
to support this hypothesis. First, although the two peripheral pul-
monary nodules on chest computed tomography (Figure 1A) were
initially thought to be metastatic lesions of malignancy, pulmonary
cryptococcoma could not be ruled out in the differential diagnosis.
The patient's serum cryptococcal antigen titer was 1024-fold,
which suggested that the patient had systemic cryptococcal dis-
ease, favoring the two pulmonary nodules as pulmonary crypto-
coccoma. Second, the patient was an 88-year-old woman, and
evidence shows that susceptibility to fungal infection in this age
group receiving rituximab-CHOP is increased compared with those
receiving CHOP alone4,10. Rituximab targets both malignant and
nonmalignant CD20-positive B cells. Although T cells play central
roles in host defense against C. neoformans, B cells participate in
early fungal clearance by producing a capsule-speciﬁc antibody11.
Antibody-mediated protection against C. neoformans pulmonary
infection is dependent on B cells12. We infer that the use of
rituximab-containing chemotherapy markedly decreasedpulmonary immunity defense against Cryptococcus, causing disease
progression in this 88-year-old woman.
In modern clinical practice, anticancer therapy utilizing mono-
clonal antibodies are extensively used, and hence, clinicians should
be on the lookout for occult fungal infection, especially in the high-
risk aged population.Acknowledgments
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